Mass spectrometric immunoassays in characterization of clinically significant proteoforms

Proteomes

Volumn 4, Issue 1, 2016, Pages

  Trenchevska, Olgica ^a   Nelson, Randall W ^a   Nedelkov, Dobrin ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; Immunoaffinity; Mass spectrometry; Posttranslational modifications; Top down analysis

Indexed keywords

EID: 85029476326     PISSN: None     EISSN: 22277382     Source Type: Journal    
DOI: 10.3390/proteomes4010013     Document Type: Review

References (121)

1. Anderson, N.L. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol. Cell. Proteom. 2005, 4, 1441-1444
2. Rifai, N.; Gillette, M.A.; Carr, S.A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983
3. Goodman, J.; Agoram, B. Analytical assay platforms for soluble target engagement biomarkers: Old favorites and emerging technologies. Bioanalysis 2013, 5, 2919-2931
4. Tighe, P.J.; Ryder, R.R.; Todd, I.; Fairclough, L.C. ELISA in the multiplex era: Potentials and pitfalls. Proteom. Clin. Appl. 2015, 9, 406-422
5. Flodin, M.; Jonsson, A.S.; Hansson, L.O.; Danielsson, L.A.; Larsson, A. Evaluation of gentian cystatin c reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2 from the cystatin c values in mg/L. Scand. J. Clin. Lab. Investig. 2007, 67, 560-567
6. Farley, A.R.; Link, A.J. Identification and quantification of protein posttranslational modifications. Methods Enzymol. 2009, 463, 725-763
7. Wu, J.R.; Zeng, R. Molecular basis for population variation: From SNPS to SAPS. FEBS Lett. 2012, 586, 2841-2845
8. Smith, L.M.; Kelleher, N.L. Consortium for Top-Down Proteomics. Proteoform: A single term describing protein complexity. Nat. Methods 2013, 10, 186-187
9. Zhao, Y.; Jensen, O.N. Modification-specific proteomics: Strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 2009, 9, 4632-4641
10. Walsh, G.; Jefferis, R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol 2006, 24, 1241-1252
11. Committee, I.E. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32, 1327-1334
12. Anderson, N.L. The clinical plasma proteome: A survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185
13. Baumann, M.; Meri, S. Techniques for studying protein heterogeneity and post-translational modifications. Expert Rev. Proteom. 2004, 1, 207-217
14. Aebersold, R.; Mann, M. Mass spectrometry-based proteomics. Nature 2003, 422, 198-207
15. Chait, B.T. Chemistry. Mass spectrometry: Bottom-up or top-down? Science 2006, 314, 65-66
16. Lin, D.; Tabb, D.L.; Yates, J.R. Large-scale protein identification using mass spectrometry. Biochim. Biophys. Acta 2003, 1646, 1-10
17. Anderson, N.L.; Anderson, N.G.; Haines, L.R.; Hardie, D.B.; Olafson, R.W.; Pearson, T.W. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by Anti-peptide Antibodies (SISCAPA). J. Proteome Res. 2004, 3, 235-244
18. Razavi, M.; Frick, L.E.; LaMarr, W.A.; Pope, M.E.; Miller, C.A.; Anderson, N.L.; Pearson, T.W. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J. Proteome Res. 2012, 11, 5642-5649
19. Mann, M. Functional and quantitative proteomics using silac. Nat. Rev. Mol. Cell Biol. 2006, 7, 952-958
20. Hennrich, M.L.; Gavin, A.C. Quantitative mass spectrometry of posttranslational modifications: Keys to confidence. Sci. Signal. 2015, 8, re5
21. Ong, S.E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D.B.; Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteom. 2002, 1, 376-386
22. Altelaar, A.F.; Frese, C.K.; Preisinger, C.; Hennrich, M.L.; Schram, A.W.; Timmers, H.T.; Heck, A.J.; Mohammed, S. Benchmarking stable isotope labeling based quantitative proteomics. J. Proteom. 2013, 88, 14-26
23. Thompson, A.; Schäfer, J.; Kuhn, K.; Kienle, S.; Schwarz, J.; Schmidt, G.; Neumann, T.; Johnstone, R.; Mohammed, A.K.; Hamon, C. Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 2003, 75, 1895-1904
24. Ross, P.L.; Huang, Y.N.; Marchese, J.N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; et al. Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteom. 2004, 3, 1154-1169
25. Fíla, J.; Honys, D. Enrichment techniques employed in phosphoproteomics. Amino Acids 2012, 43, 1025-1047
26. Silva, A.M.; Vitorino, R.; Domingues, M.R.; Spickett, C.M.; Domingues, P. Post-translational modifications and mass spectrometry detection. Free Radic. Biol. Med. 2013, 65, 925-941
27. Garcia, B.A. What does the future hold for Top Down mass spectrometry? J. Am. Soc. Mass Spectrom. 2010, 21, 193-202
28. Zhang, H.; Ge, Y. Comprehensive analysis of protein modifications by top-down mass spectrometry. Circ. Cardiovasc. Genet. 2011, 4, 711
29. McLafferty, F.W.; Breuker, K.; Jin, M.; Han, X.; Infusini, G.; Jiang, H.; Kong, X.; Begley, T.P. Top-down MS, a powerful complement to the high capabilities of proteolysis proteomics. FEBS J 2007, 274, 6256-6268
30. Siuti, N.; Kelleher, N.L. Decoding protein modifications using top-down mass spectrometry. Nat. Methods 2007, 4, 817-821
31. Cooper, H.J.; Håkansson, K.; Marshall, A.G. The role of electron capture dissociation in biomolecular analysis. Mass Spectrom. Rev. 2005, 24, 201-222
32. Sarbu, M.; Ghiulai, R.M.; Zamfir, A.D. Recent developments and applications of electron transfer dissociation mass spectrometry in proteomics. Amino Acids 2014, 46, 1625-1634
33. Zubarev, R.A. Electron-capture dissociation tandem mass spectrometry. Curr. Opin. Biotechnol. 2004, 15, 12-16
34. Soares, R.; Pires, E.; Almeida, A.M.; Santos, R.; Gomes, R.; Koci, K.; Franco, C.F.; Coelho, A.V. Tandem mass spectrometry of peptides. In Tandem Mass Spectrometry-Applications and Principles; Prasain, J.K., Ed.; InTech: Rijeka, Croatia, 2012; Chapter 2; pp. 35-36
35. Elviri, L. ETD and ECD mass spectrometry fragmentation for the characterization of protein post translational modifications. In Tandem Mass Spectrometry-Applications and Principles; InTech: Rijeka, Croatia, 2012; Chapter 7; pp. 161-178
36. Na, S.; Paek, E. Software eyes for protein post-translational modifications. Mass Spectrom. Rev. 2015, 34, 133-147
37. Chen, Z.; Caulfield, M.P.; McPhaul, M.J.; Reitz, R.E.; Taylor, S.W.; Clarke, N.J. Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin. Chem. 2013, 59, 1349-1356
38. Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007, 6, 2212-2229
39. Guthals, A.; Bandeira, N. Peptide identification by tandem mass spectrometry with alternate fragmentation modes. Mol Cell Proteomics 2012, 11, 550-557
40. Rauh, M. LC-MS/MS for protein and peptide quantification in clinical chemistry. J. Chromatogr. B 2012, 883-884, 59-67
41. Messana, I.; Cabras, T.; Iavarone, F.; Vincenzoni, F.; Urbani, A.; Castagnola, M. Unraveling the different proteomic platforms. J. Sep. Sci. 2013, 36, 128-139
42. Weiß, F.; van den Berg, B.H.; Planatscher, H.; Pynn, C.J.; Joos, T.O.; Poetz, O. Catch and measure-mass spectrometry-based immunoassays in biomarker research. Biochim. Biophys. Acta 2014, 1844, 927-932
43. Angel, T.E.; Aryal, U.K.; Hengel, S.M.; Baker, E.S.; Kelly, R.T.; Robinson, E.W.; Smith, R.D. Mass spectrometry-based proteomics: Existing capabilities and future directions. Chem. Soc. Rev. 2012, 41, 3912-3928
44. Lacey, J.M.; Bergen, H.R.; Magera, M.J.; Naylor, S.; O'Brien, J.F. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin. Chem. 2001, 47, 513-518
45. Bystrom, C.; Sheng, S.; Zhang, K.; Caulfield, M.; Clarke, N.J.; Reitz, R. Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS ONE 2012, 7, e43457
46. Bystrom, C.E.; Sheng, S.; Clarke, N.J. Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: Determination of insulin-like growth factor-1. Anal. Chem. 2011, 83, 9005-9010
47. Nelson, R.W.; Krone, J.R.; Bieber, A.L.; Williams, P. Mass spectrometric immunoassay. Anal. Chem. 1995, 67, 1153-1158
48. Nelson, R.W.; Borges, C.R. Mass spectrometric immunoassay revisited. J. Am. Soc. Mass Spectrom. 2011, 22, 960-968
49. Tubbs, K.A.; Nedelkov, D.; Nelson, R.W. Detection and quantification of β-2-microglobulin using mass spectrometric immunoassay. Anal. Biochem. 2001, 289, 26-35
50. Sherma, N.D.; Borges, C.R.; Trenchevska, O.; Jarvis, J.W.; Rehder, D.S.; Oran, P.E.; Nelson, R.W.; Nedelkov, D. Mass spectrometric immunoassay for the qualitative and quantitative analysis of the cytokine macrophage migration inhibitory factor (MIF). Proteome Sci. 2014, 12, 52
51. Trenchevska, O.; Sherma, N.D.; Oran, P.E.; Reaven, P.D.; Nelson, R.W.; Nedelkov, D. Quantitative mass spectrometric immunoassay for the chemokine rantes and its variants. J. Proteom. 2015, 116, 15-23
52. Oran, P.E.; Trenchevska, O.; Nedelkov, D.; Borges, C.R.; Schaab, M.R.; Rehder, D.S.; Jarvis, J.W.; Sherma, N.D.; Shen, L.; Krastins, B.; et al. Parallel workflow for high-throughput (>1000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay. PLoS ONE 2014, 9, e92801
53. Rehder, D.S.; Gundberg, C.M.; Booth, S.L.; Borges, C.R. Gamma-carboxylation and fragmentation of osteocalcin in human serum defined by mass spectrometry. Mol. Cell. Proteom. 2015, 14, 1546-1555
54. Rehder, D.S.; Nelson, R.W.; Borges, C.R. Glycosylation status of vitamin d binding protein in cancer patients. Protein Sci. 2009, 18, 2036-2042
55. Borges, C.R.; Rehder, D.S.; Jarvis, J.W.; Schaab, M.R.; Oran, P.E.; Nelson, R.W. Full-length characterization of proteins in human populations. Clin. Chem. 2010, 56, 202-211
56. Strathmann, F.G.; Hoofnagle, A.N. Current and future applications of mass spectrometry to the clinical laboratory. Am. J. Clin. Pathol. 2011, 136, 609-616
57. Clarke, N.J.; Hoofnagle, A.N. Mass spectrometry continues its march into the clinical laboratory. Clin. Lab. Med. 2011, 31, IX-XI
58. Grant, R.P.; Hoofnagle, A.N. From lost in translation to paradise found: Enabling protein biomarker method transfer by mass spectrometry. Clin. Chem. 2014, 60, 941-944
59. Carr, S.A.; Abbatiello, S.E.; Ackermann, B.L.; Borchers, C.; Domon, B.; Deutsch, E.W.; Grant, R.P.; Hoofnagle, A.N.; Hüttenhain, R.; Koomen, J.M.; et al. Targeted peptide measurements in biology and medicine: Best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell. Proteom. 2014, 13, 907-917
60. Armbruster, D.A.; Pry, T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 2008, 29 (Suppl. S1), S49-S52
61. Bland, J.M.; Altman, D.G. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 1999, 8, 135-160
62. Passing, H.; Bablok, W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J. Clin. Chem. Clin. Biochem. 1983, 21, 709-720
63. Stapels, M.D.; Barofsky, D.F. Complementary use of MALDI and esi for the HPLC-MS/MS analysis of DNA-binding proteins. Anal. Chem 2004, 76, 5423-5430
64. Dreisewerd, K. The desorption process in maldi. Chem. Rev. 2003, 103, 395-426
65. Albrethsen, J. Reproducibility in protein profiling by maldi-tof mass spectrometry. Clin. Chem. 2007, 53, 852-858
66. Yassine, H.; Borges, C.R.; Schaab, M.R.; Billheimer, D.; Stump, C.; Reaven, P.; Lau, S.S.; Nelson, R. Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: Potential applications to cardiovascular disease and diabetes. Proteom. Clin. Appl. 2013, 7, 528-540
67. Nedelkov, D.; Shaik, S.; Trenchevska, O.; Aleksovski, V.; Mitrevski, A.; Stojanoski, K. Targeted mass spectrometric immunoassay for detection of cystatin c isoforms in cerebrospinal fluid. Open Proteom. J. 2008, 1, 54-58
68. Meyer, K.; Ueland, P.M. Targeted quantification of c-reactive protein and cystatin c and its variants by immuno-MALDI-MS. Anal. Chem. 2014, 86, 5807-5814
69. Végvári, A.; Sjödin, K.; Rezeli, M.; Malm, J.; Lilja, H.; Laurell, T.; Marko-Varga, G. Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring. Mol. Cell. Proteom. 2013, 12, 2761-2773
70. Henze, M.; Patrick, S.E.; Hinken, A.; Scruggs, S.B.; Goldspink, P.; de Tombe, P.P.; Kobayashi, M.; Ping, P.; Kobayashi, T.; Solaro, R.J. New insights into the functional significance of the acidic region of the unique N-terminal extension of cardiac troponin i. Biochim. Biophys. Acta 2013, 1833, 823-832
71. Wang, D.; McCully, M.E.; Luo, Z.; McMichael, J.; Tu, A.Y.; Daggett, V.; Regnier, M. Structural and functional consequences of cardiac troponin C l57Q and I61Q Ca2+-desensitizing variants. Arch. Biochem. Biophys. 2013, 535, 68-75
72. Steinkasserer, A.; Weiss, E.H.; Schwaeble, W.; Linke, R.P. Heterogeneity of human serum amyloid A protein. Five different variants from one individual demonstrated by cdna sequence analysis. Biochem. J. 1990, 268, 187-193
73. Malle, E.; Steinmetz, A.; Raynes, J.G. Serum amyloid A (SAA): An acute phase protein and apolipoprotein. Atherosclerosis 1993, 102, 131-146
74. Raynes, J.G.; McAdam, K.P. Serum amyloid A isoforms in inflammation. Scand. J. Immunol 1991, 33, 657-666
75. Ducret, A.; Bruun, C.F.; Bures, E.J.; Marhaug, G.; Husby, G.; Aebersold, R. Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Electrophoresis 1996, 17, 866-876
76. Farwig, Z.N.; McNeal, C.J.; Little, D.; Baisden, C.E.; Macfarlane, R.D. Novel truncated isoforms of constitutive serum amyloid A detected by MALDI mass spectrometry. Biochem. Biophys. Res. Commun. 2005, 332, 352-356
77. Uhlar, C.M.; Whitehead, A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 1999, 265, 501-523
78. Fyfe, A.I.; Rothenberg, L.S.; DeBeer, F.C.; Cantor, R.M.; Rotter, J.I.; Lusis, A.J. Association between serum amyloid A proteins and coronary artery disease: Evidence from two distinct arteriosclerotic processes. Circulation 1997, 96, 2914-2919
79. Ristori, G.; Laurenti, F.; Stacchini, P.; Gasperini, C.; Buttinelli, C.; Pozzilli, C.; Salvetti, M. Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 1998, 88, 9-12
80. Artl, A.; Marsche, G.; Lestavel, S.; Sattler, W.; Malle, E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 763-772
81. Yamada, T.; Wada, A.; Itoh, Y.; Itoh, K. Serum amyloid A1 alleles and plasma concentrations of serum amyloid A. Amyloid 1999, 6, 199-204
82. MacGregor, A.J.; Gallimore, J.R.; Spector, T.D.; Pepys, M.B. Genetic effects on baseline values of c-reactive protein and serum amyloid A protein: A comparison of monozygotic and dizygotic twins. Clin. Chem. 2004, 50, 130-134
83. Kiernan, U.A.; Tubbs, K.A.; Nedelkov, D.; Niederkofler, E.E.; Nelson, R.W. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett. 2003, 537, 166-170
84. Sipe, J. Revised nomenclature for serum amyloid A (SAA). Nomenclature committee of the international society of amyloidosis. Part 2. Amyloid 1999, 6, 67-70
85. Trenchevska, O.; Kamcheva, E.; Nedelkov, D. Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J. Proteome Res. 2010, 9, 5969-5973
86. Kiernan, U.A.; Phillips, D.A.; Trenchevska, O.; Nedelkov, D. Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS ONE 2011, 6, e17282
87. Kiernan, U.A.; Tubbs, K.A.; Gruber, K.; Nedelkov, D.; Niederkofler, E.E.; Williams, P.; Nelson, R.W. High-throughput protein characterization using mass spectrometric immunoassay. Anal. Biochem. 2002, 301, 49-56
88. Nelson, R.W.; Nedelkov, D.; Tubbs, K.A.; Kiernan, U.A. Quantitative mass spectrometric immunoasay of insulin like growth factor 1. J. Proteome Res. 2004, 3, 851-855
89. Borges, C.R.; Oran, P.E.; Buddi, S.; Jarvis, J.W.; Schaab, M.R.; Rehder, D.S.; Rogers, S.P.; Taylor, T.; Nelson, R.W. Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Clin. Chem. 2011, 57, 719-728
90. Yassine, H.N.; Jackson, A.M.; Reaven, P.D.; Nedelkov, D.; Nelson, R.W.; Lau, S.S.; Borchers, C.H. The application of multiple reaction monitoring to assess ApoA-I methionine oxidations in diabetes and cardiovascular disease. Transl. Proteom. 2014, 4-5, 18-24
91. Yassine, H.N.; Trenchevska, O.; Ramrakhiani, A.; Parekh, A.; Koska, J.; Walker, R.W.; Billheimer, D.; Reaven, P.D.; Yen, F.T.; Nelson, R.W.; et al. The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides. PLoS ONE 2015, 10, e0144138
92. Niederkofler, E.E.; Tubbs, K.A.; Gruber, K.; Nedelkov, D.; Kiernan, U.A.; Williams, P.; Nelson, R.W. Determination of β-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal. Chem. 2001, 73, 3294-3299
93. Niederkofler, E.E.; Kiernan, U.A.; O'Rear, J.; Menon, S.; Saghir, S.; Protter, A.A.; Nelson, R.W.; Schellenberger, U. Detection of endogenous b-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 2008, 1, 258-264
94. Oran, P.E.; Jarvis, J.W.; Borges, C.R.; Nelson, R.W. C-peptide microheterogeneity in type 2 diabetes populations. Proteom. Clin. Appl. 2010, 4, 106-111
95. Kiernan, U.A.; Addobbati, R.; Nedelkov, D.; Nelson, R.W. Quantitative multiplexed c-reactive protein mass spectrometric immunoassay. J. Proteome Res. 2006, 5, 1682-1687
96. Kiernan, U.A.; Nedelkov, D.; Niederkofler, E.E.; Tubbs, K.A.; Nelson, R.W. High-throughput affinity mass spectrometry. Methods Mol. Biol. 2006, 328, 141-150
97. Trenchevska, O.; Nedelkov, D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 2011, 9, 19
98. Borges, C.R.; Jarvis, J.W.; Oran, P.E.; Nelson, R.W. Population studies of vitamin d binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J. Proteome Res. 2008, 7, 4143-4153
99. Tubbs, K.A.; Kiernan, U.A.; Niederkofler, E.E.; Nedelkov, D.; Bieber, A.L.; Nelson, R.W. High-throughput MS-based protein phenotyping: Application to haptoglobin. Proteomics 2005, 5, 5002-5007
100. Oran, P.E.; Jarvis, J.W.; Borges, C.R.; Sherma, N.D.; Nelson, R.W. Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteom. Clin. Appl. 2011, 5, 454-459
101. Lopez, M.F.; Rezai, T.; Sarracino, D.A.; Prakash, A.; Krastins, B.; Athanas, M.; Singh, R.J.; Barnidge, D.R.; Oran, P.; Borges, C.; et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56, 281-290
102. Oran, P.E.; Sherma, N.D.; Borges, C.R.; Jarvis, J.W.; Nelson, R.W. Intrapersonal and populational heterogeneity of the chemokine rantes. Clin. Chem. 2010, 56, 1432-1441
103. Kiernan, U.A.; Tubbs, K.A.; Nedelkov, D.; Niederkofler, E.E.; Nelson, R.W. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem. Biophys. Res. Commun. 2002, 297, 401-405
104. Yassine, H.N.; Trenchevska, O.; He, H.; Borges, C.R.; Nedelkov, D.; Mack, W.; Kono, N.; Koska, J.; Reaven, P.D.; Nelson, R.W. Serum amyloid A truncations in type 2 diabetes mellitus. PLoS ONE 2015, 10, e0115320
105. Kiernan, U.A.; Nedelkov, D.; Tubbs, K.A.; Niederkofler, E.E.; Nelson, R.W. Proteomic characterization of novel serum amyloid p component variants from human plasma and urine. Proteomics 2004, 4, 1825-1829
106. Trenchevska, O.; Kamcheva, E.; Nedelkov, D. Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 2011, 11, 3633-3641
107. Trenchevska, O.; Schaab, M.R.; Nelson, R.W.; Nedelkov, D. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods 2015, 81, 86-92
108. Niederkofler, E.E.; Tubbs, K.A.; Kiernan, U.A.; Nedelkov, D.; Nelson, R.W. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J. Lipid Res. 2003, 44, 630-639
109. Nedelkov, D.; Nelson, R.W.; Kiernan, U.A.; Niederkofler, E.E.; Tubbs, K.A. Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry. FEBS Lett. 2003, 536, 130-134
110. Kiernan, U.A.; Nedelkov, D.; Nelson, R.W. Multiplexed mass spectrometric immunoassay in biomarker research: A novel approach to the determination of a myocardial infarct. J. Proteome Res. 2006, 5, 2928-2934
111. Nedelkov, D.; Tubbs, K.A.; Niederkofler, E.E.; Kiernan, U.A.; Nelson, R.W. High-throughput comprehensive analysis of human plasma proteins: A step toward population proteomics. Anal. Chem. 2004, 76, 1733-1737
112. Trenchevska, O.; Phillips, D.A.; Nelson, R.W.; Nedelkov, D. Delineation of concentration ranges and longitudinal changes of human plasma protein variants. PLoS ONE 2014, 9, e100713
113. Krastins, B.; Prakash, A.; Sarracino, D.A.; Nedelkov, D.; Niederkofler, E.E.; Kiernan, U.A.; Nelson, R.; Vogelsang, M.S.; Vadali, G.; Garces, A.; et al. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 2013, 46, 399-410
114. Nedelkov, D. Population proteomics: Investigation of protein diversity in human populations. Proteomics 2008, 8, 779-786
115. Nedelkov, D.; Phillips, D.A.; Tubbs, K.A.; Nelson, R.W. Investigation of human protein variants and their frequency in the general population. Mol. Cell. Proteom. 2007, 6, 1183-1187
116. Nedelkov, D.; Kiernan, U.A.; Niederkofler, E.E.; Tubbs, K.A.; Nelson, R.W. Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. USA 2005, 102, 10852-10857
117. Nedelkov, D. Population proteomics: Addressing protein diversity in humans. Expert Rev. Proteom. 2005, 2, 315-324
118. Nedelkov, D.; Kiernan, U.A.; Niederkofler, E.E.; Tubbs, K.A.; Nelson, R.W. Population proteomics: The concept, attributes, and potential for cancer biomarker research. Mol. Cell. Proteom. 2006, 5, 1811-1818
119. Jong, M.C.; Hofker, M.H.; Havekes, L.M. Role of ApoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 472-484
120. Bondarenko, P.V.; Cockrill, S.L.; Watkins, L.K.; Cruzado, I.D.; Macfarlane, R.D. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J. Lipid Res. 1999, 40, 543-555
121. Surinova, S.; Schiess, R.; Hüttenhain, R.; Cerciello, F.; Wollscheid, B.; Aebersold, R. On the development of plasma protein biomarkers. J. Proteome Res. 2011, 10, 5-16